A detailed history of Wells Fargo & Company transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Wells Fargo & Company holds 1,000 shares of CGTX stock, worth $440. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$440
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.66 - $2.62 $1,417 - $2,237
854 Added 584.93%
1,000 $1,000
Q1 2024

May 10, 2024

BUY
$1.78 - $2.53 $17 - $25
10 Added 7.35%
146 $0
Q4 2023

Feb 09, 2024

BUY
$0.96 - $2.42 $7 - $19
8 Added 6.25%
136 $0
Q3 2023

Nov 13, 2023

SELL
$1.25 - $1.9 $11 - $17
-9 Reduced 6.57%
128 $0
Q2 2023

Aug 15, 2023

BUY
$1.56 - $3.38 $20 - $43
13 Added 10.48%
137 $0
Q1 2023

May 12, 2023

SELL
$1.51 - $2.3 $57,962 - $88,287
-38,386 Reduced 99.68%
124 $0
Q4 2022

Feb 13, 2023

SELL
$1.17 - $3.51 $44,947 - $134,843
-38,417 Reduced 49.94%
38,510 $80,000
Q3 2022

Nov 14, 2022

BUY
$1.63 - $3.6 $97 - $216
60 Added 0.08%
76,927 $146,000
Q2 2022

Aug 12, 2022

BUY
$1.5 - $3.45 $115,264 - $265,108
76,843 Added 320179.16%
76,867 $162,000
Q4 2021

Feb 14, 2022

BUY
$5.1 - $12.98 $122 - $311
24 New
24 $0

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $9.99M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.